Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03892564 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream
A Phase 1 study of Phototoxicity, sponsored by MC2 Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03892564 is a Phase 1 study of Phototoxicity that has completed, run by MC2 Therapeutics. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03892564, a Phase 1 study of Phototoxicity, has completed, sponsored by MC2 Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is a 4-day, randomized study to determine the phototoxic potential of MC2-01 Cream when topical application to healthy skin is followed by light exposure.
Conditions Studied
Interventions
- DRUG MC2-01 Cream, irradiation
- DRUG MC2-01 Cream, no irradiation
- DRUG MC2-01 vehicle, irradiation
- DRUG MC2-01 vehicle, no irradiation
- DRUG Control, irradiation
Study Locations (1)
New Jersey
- TKL Research Inc - Fair Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-02-27 |
| Est. Completion | 2019-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03892564
The ClinicalTrials.gov registry entry for NCT03892564 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MC2 Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Phototoxicity appearing as the primary indexed condition, and to 5 interventions - of which MC2-01 Cream, irradiation is the first listed.
NCT03892564 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT03892564 about?
NCT03892564 is a clinical study titled "Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream". This trial is a 4-day, randomized study to determine the phototoxic potential of MC2-01 Cream when topical application to healthy skin is followed by light exposure.
What is the current status of trial NCT03892564?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2019-02-27. Estimated completion is 2019-03-09.
What conditions does trial NCT03892564 study?
This clinical trial studies the following conditions: Phototoxicity.
What interventions are being tested in trial NCT03892564?
The interventions under investigation include: MC2-01 Cream, irradiation (DRUG), MC2-01 Cream, no irradiation (DRUG), MC2-01 vehicle, irradiation (DRUG), MC2-01 vehicle, no irradiation (DRUG), Control, irradiation (DRUG).
Who is sponsoring clinical trial NCT03892564?
This trial is sponsored by MC2 Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03892564 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.